Healthcare industry

Article - 22/03/2019

Personalised therapies for treating metastasing breast cancer

Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

Press release - 10/12/2018

High distinction for stem cell researcher Andreas Trumpp

This year's State Research Prize of Baden-Württemberg awarded for outstanding achievements in applied research goes to Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). Theresia Bauer, State Minister of Science, Research and the Arts, presented the award, which carries a monetary prize of €100.000, at a festive ceremony on December 10, 2018.

One year after its seed financing, SpinDiag GmbH closes a second financing round of EUR 3 million (USD 3.4 million) as planned. The financing will enable SpinDiag to complete the product development of its first product for screening for antibiotic-resistant bacteria and to start clinical trials. This will pave the way for regulatory approval in the EU.

Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.

Article - 21/08/2018

Parkinson's disease: vitamin B3 has a positive effect on nerve cells

Parkinson's disease is one of the most common neurodegenerative diseases in the world. There are around 4.1 million sufferers worldwide. It is characterised by motor impairments that result from the death of certain nerve cells in the brain. Researchers at the University of Tübingen have now discovered that vitamin B3 has a positive effect on damaged nerve cells and can boost their energy metabolism.

Company profile - 31/07/2018

Acousia Therapeutics: medicines for deafness

Deafness is one of the most common sensory disorders in the world: in Germany alone, around eleven million people suffer from hearing loss. So far there is no real therapy, the symptoms can only be alleviated to a greater or lesser degree. This is what researchers from the Tübingen-based company Acousia Therapeutics want to change: they have identified drug candidates that can protect sensory hair cells and support their function.

Press release - 04/07/2018

Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

Viscofan BioEngineering, the biomedical business unit of the world market leader for collagenous sausage casings Viscofan announced today that the Spanish Agency for Medicines (AEMPS) has given green light to carry out a clinical phase-I-trial with Viscofan BioEngineering’s first product for regenerative medicine. The novel therapy consisting of stem cells on a collagenous carrier membrane can now be tested on ten patients suffering from severe…

Article - 23/05/2018

Bacteriophages as alternatives to antibiotics

Multidrug-resistant bacteria are resistant to many existing antibiotics and can be difficult to treat. There are increasing numbers of them worldwide. Although novel antibiotics are being developed, there are far too few of them to tackle the rise of multidrug-resistant bacteria. In Eastern Europe, doctors have been treating bacterial infections with viruses that infect bacteria, so-called bacteriophages, for almost 100 years.

Article - 25/04/2018

Resistance, immunity and malaria vaccination

People who have survived a malaria infection often develop immunity to the disease. International malaria research is aimed at exploiting a person's natural immunity in order to treat malaria effectively and avoid resistance to previously effective drugs. These new approaches also raise hopes that one day countries at high risk of malaria may be able to eradicate the devastating disease.

Article - 05/04/2018

Crossing the valley of death with translational cancer research

It can take many decades before promising research results become therapies that have a positive effect on cancer patients. Most research projects go adrift somewhere between the laboratory and the bedside in the so-called "valley of death". Projects carried out at the DKFZ show that translational cancer research actually works.

Alternative to animal experiments - 21/03/2018

Drug tests using miniature organs

At present, potential new drugs have to be tested on animals before they can be used on humans. However, results obtained from animals are not always transferrable to the situation in humans, which is why researchers around the world have long been seeking alternatives. Miniature human organs that can be used to test the efficacy of potential human drugs might provide a solution.

Article - 19/03/2018

Regenerative medicine: curing rather than simply treating diseases

Some scientists refer to the latest developments in the field of regenerative medicine as the "next revolution in medicine". With the help of gene therapies or stem cells, regenerative medicine aims not only to treat disease symptoms, but to cure them at source. Some approaches are already being used to treat patients and several others are close to application.

Big Data - 13/03/2018

“More data does not automatically imply more knowledge“

In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted.

Article - 21/02/2018

HepaRegeniX – a start-up is taking it up a step!

HepaRegeniX, a biotech company founded in 2016, specialises in developing drugs that restore the regenerative capacity of diseased livers. The three founders of the biotech start-up, Prof. Dr. Lars Zender, Prof. Dr. Stefan Laufer and Dr. Wolfgang Albrecht, anticipate starting clinical testing of the first drug candidate in 2019.

Article - 18/01/2018

Medications that target metastasing tumours

Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.

CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.

Big Data - 14/12/2017

Looking at the whole genome raises new questions

Research laboratories around the world have long focused on studying the whole human genome. It is hoped that knowing the whole human genome will improve diagnostics and enable more specific therapies. Although genome analysis has not yet reached routine clinical application, whole genome sequencing has already raised many ethical and legal issues - for researchers, physicians and patients.

Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.

Company profile - 04/09/2017

Mireca: a new drug for stopping the progression of eye diseases

A team of researchers from several EU countries has developed a new drug that stops the progression of hereditary retinal diseases. The project partners founded a company called Mireca Medicines GmbH in the city of Tübingen to bring the drug to market.

Article - 24/07/2017

Cancer medicine development as a science and industry partnership

The German Cancer Research Center (DKFZ) and Bayer AG are collaborating on a strategic partnership focusing on the development of innovative cancer therapies. The two partners have developed an active substance which selectively blocks a mutation of a metabolic enzyme that occurs in certain types of cancer. The substance has been successfully tested in preclinical studies and is now also being tested in a clinical trial on patients with brain…

Article - 04/07/2017

Ruxolitinib – successful graft-versus-host disease treatment

Graft-versus-host disease is a serious complication in leukaemia patients who have been given a blood stem cell transplant from a genetically different person. Prof. Dr. Nikolas von Bubnoff and Prof. Dr. Robert Zeiser from the Department of Haematology, Oncology and Stem Cell Transplantation at Freiburg University Medical Centre initiated a Germany-wide study to show that an active substance called ruxolitinib has a promising therapeutic effect.…

Article - 26/06/2017

Hope for mRNA vaccines despite damper

The pressure is on to develop novel vaccines based on messenger RNA and aimed at combating cancer and protecting against pandemics. Although mRNA vaccination as a cancer monotherapy has suffered a setback this year, the industry is nevertheless confident that it will succeed because of existing proof that mRNA vaccines stimulate the body's immune defence.

Article - 31/05/2017

Peritoneal cancer – long-term survival with good quality of life

Thanks to an innovative treatment procedure that has been in use since 2005, surgeons from Tübingen University Hospital have been able to prolong the survival of patients with peritoneal cancer and give them a higher quality of life. This is done using a technique based on complex surgery followed by immediate intraoperative local chemotherapy on the peritoneum.

Article - 24/05/2017

Ralf Reski: from moss to humans

Prof. Dr. Ralf Reski conducts basic research at the University of Freiburg. But this is not all the well-known plant biotechnologist does. He also wants his ideas to become concrete products. This is why he established Greenovation Biotech GmbH, a company which produces novel drugs in mosses. The company’s first moss-produced drug candidate – Moss-aGal – a recombinant form of human α-galactosidase, is now being tested in a phase I clinical trial.…

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. As a seed stage investor, High-Tech Gründerfonds (HTGF) will finance this innovative technique and the preparations for Phase II of the clinical trial, which begins in spring 2018. Further…